07:00 , Aug 29, 2005 |  BC Week In Review  |  Company News

Prima, Austin Research Institute deal

PRR completed its acquisition of the institute's share and option holdings in four PRR subsidiaries (see BioCentury, Aug.15). PRR now owns all shares of Oncomab Pty Ltd., Panvax Ltd., Cancer Vac Pty Ltd., and 92.5%...
07:00 , Aug 15, 2005 |  BC Week In Review  |  Company News

Prima BioMed, Austin Research Institute deal

PRR proposed to acquire the institute's share and option holdings in four PRR subsidiaries for 15 million shares. The deal would be valued at A$1.7 million ($1.3 million) based on PRR's close of A$0.12 on...
07:00 , Jul 21, 2003 |  BC Week In Review  |  Clinical News

Cancer vaccine: Phase Ib

PRR's Cancer Vac subsidiary reported that 2 patients from a Phase Ib trial have continued therapy for 18 months without disease progression as measured by tumor size or by levels of tumor markers in patients'...
08:00 , Oct 28, 2002 |  BC Week In Review  |  Clinical News

Cancer vaccine: Phase I

Final results from a previously reported Australian Phase I trial in 10 patients showed that all patients given the vaccine had tumor-specific immune responses. PRR's Cancer Vac Ltd. subsidiary said that there was no treatment-related...
07:00 , May 13, 2002 |  BC Week In Review  |  Clinical News

Cancer vaccine: Phase I

Interim results from an Australian Phase I trial in 10 patients showed that all 8 patients who have completed treatment showed tumor specific immune responses. PRR's Cancer Vac Ltd. subsidiary said that there was no...